Last Updated on June 30, 2021 by The Health Master
Dr Reddy’s will supply to major government as well as private hospitals across India. In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India.
2-DG manufactured by Dr Reddy’s has a purity of 99.5 per cent and is being sold commercially under the brand name 2DG. The maximum retail price (MRP) of each sachet has been fixed at Rs 990, with a subsidized rate offered to government institutions.
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s 2-DG is an oral drug.
It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe C-19 patients as an adjunct therapy to the existing standard of care. Emergency use approval for anti-C-19 therapeutic application of the drug was granted on May 1, 2021.
Dr G Satheesh Reddy, Secretary, Department of Defence (R&D) and Chairman, DRDO said, “We are pleased to have worked closely with our long-term industry partner Dr Reddy’s Laboratories, Hyderabad, for testing 2-DG as a therapeutic application in the treatment of C-19 patients. DRDO has been contributing in the fight against the C-19 pandemic with its spin-off technologies.”
Satish Reddy, Chairman, Dr Reddy’s said, “2-DG is yet another addition to our C-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine. We are extremely pleased to have partnered with DRDO in our collective fight against the C-19 pandemic.”